Role of prothrombin 19911 A>G polymorphism, blood group and male gender in patients with venous thromboembolism: Results of a German cohort study

Verena Limperger1 · Gili Kenet2,3 · Bettina Kiesau1 · Max Köther1 · Malin Schmeiser1 · Florian Langer4 · David Juhl5 · Maria Shneyder1 · Andre Franke6 · Ulrich K. Klostermeier1 · Rolf Meisters7 · Frank Rühle8 · Monika Stoll8,9 · Dagmar Steppat5 · Dorothee Kowalski1 · Angela Rocke1 · Piotr Kuta1 · Tido Bajorat1 · Antje Torge1 · Bruno Neuner10 · Ralf Junker1 · Ulrike Nowak-Göttl1

Published online: 27 June 2020
© The Author(s) 2020

Abstract

The role of the A>G polymorphism at position 19911 in the prothrombin gene (factor [F] 2 at rs3136516) as a risk factor for venous thromboembolism [VTE] is still unclear. To evaluate the presence of the F2 polymorphism in VTE patients compared to healthy blood donors and to adjust the results for common inherited thrombophilias [IT], age at onset and blood group [BG], and to calculate the risk of VTE recurrence. We investigated 1012 Caucasian patients with a diagnosis of VTE for the presence of the F2 rs3136516 polymorphism and compared these with 902 healthy blood donors. Odds ratios [OR] together with their 95% confidence intervals were calculated adjusted for F5 at rs6025, F2 at rs1799963, blood group, age and gender. In addition, we evaluated the risk of recurrent VTE during patient follow-up calculating hazard ratios [HR] together with their 95% CI. Compared with the AA wildtype, the F2 GG and AG genotypes (rs3136516) were associated with VTE (OR 1.48 and 1.45). The OR in F5 carriers compared to controls was 5.68 and 2.38 in patients with F2 (rs1799963). BG “non-O” was significantly more often diagnosed in patients compared to BG “O” (OR 2.74). VTE recurrence more often occurred in males (HR 2.3) and in carriers with combined thrombophilia (HR 2.11). Noteworthy, the rs3136516 polymorphism alone was not associated significantly with recurrence. In Caucasian patients with VTE the F2 GG/GA genotypes (rs3136516) were moderate risk factors for VTE. Recurrence was associated with male gender and combined thrombophilia.

Keywords Prothrombin 19911 A>G polymorphism · Thrombosis · Recurrence · Male gender

Introduction

Acquired risk factors such as surgery, immobilization, pregnancy, smoking, oral contraceptives and obesity, as well as inherited risk factors simultaneously contribute to the onset of venous thromboembolism [VTE] [1–3]. Rare inherited risk factors such as antithrombin-, protein C- and protein S deficiency are considered as high risk factors for VTE, whereas the factor [F] 5 [rs6025] and F2 [rs1799963] mutations are considered as more commonly diagnosed but being rather mild risk factors [1–5]. The A>G polymorphism at position 19911 of the prothrombin gene, e.g. F2 at rs3136516, located in intron 13 of the prothrombin gene is associated with increased plasma prothrombin levels, but its role as a risk factor for VTE is still unclear [6–11]. There is a small number of case control studies investigating the role of the F2 at rs3136516 polymorphism and its association...
with VTE. Of these, two reports showed a moderate risk for VTE [8, 9], whereas another study showed no statistically significance [10].

Therefore, the objectives of this study were to (i) evaluate the presence of the prothrombin 19911 A>G polymorphism in adolescent and younger adult Caucasian VTE in- and out-patients compared to healthy blood donors and to adjust the results obtained for common inherited thrombophilias [IT], age at onset and blood group [BG]. The second objective of this study was to (ii) calculate in the patient cohort the risk of VTE recurrence independently of gender, common mild ITs including the F2 at rs3136516 polymorphism, age at first VTE onset and blood group.

Material and methods

Study population

Consecutive patients with a first symptomatic VTE were recruited between December 2008 and 2018 whether or not prothrombotic risk factors were present. Screening of thrombophilia was performed in 1012 adolescent and adult patients [14 to < 60 years] and 902 healthy blood donors [18 to < 61 years] from the same catchment area.

Inclusion and exclusion criteria

Corresponding to the following criteria patients were included into the study: (i) age from puberty status > Tanner 2 [12] to 60 years at first VTE onset, (ii) objectively confirmed thrombosis and re-thrombosis with established imaging procedures such as Duplex- or Doppler-ultrasonography, computed tomography or magnetic resonance tomography for venous thrombosis and spiral computed pulmonary angiography or lung perfusion scintigraphy for pulmonary embolism. Patients were excluded from the study when they suffer from (i) central line-associated VTE, VTE linked to malignancy, antiphospholipid syndrome, inherited antithrombin-, protein C- or protein S-deficiency or (ii) when they were lost to follow-up or did not abide by the follow-up visits.

Study aims

The primary study objective was to determine the individual VTE risk of the F2 mutation at rs3136516 in Caucasian VTE patients [n = 1012] compared to healthy blood donors [n = 902] adjusted for (i) common ITs, e.g. F5 at rs6025 and F2 at rs1799963, age at onset and blood group [1–3, 13, 14]. The secondary study objective was to investigate the time to VTE recurrence after withdrawal of antithrombotic therapy, adjust for the above listed potential confounders.

Clinical procedures

Following a first VTE onset (in- and outpatients) and during regular follow-up visits [3–6 months (adolescents), 9–12 months, 2 years (adults)] we evaluated and re-evaluated patient’s disease history and possible risk factors causing VTE, such as the use of oral contraceptives, pregnancy, obesity, immobilization, surgery and smoking. Clinical data collection also included laboratory test results, antithrombotic therapy, including adherence to anticoagulation and duration and family history of VTE. Adolescent and adult patients were treated independently from the underlying IT risk factors according to the latest antithrombotic VTE therapy guideline. (Online Supplement) [15–17].

Details on blood sample collection are depicted in detail in the online supplement.

Laboratory analyses

With written or oral parental consent mutations in F2 at rs3136516, F5 at rs6025 and F2 at rs1799963 as well as circulating levels of antithrombin, coagulation inhibitors, d-dimer concentration as well as lupus anticoagulants and antiphospholipid antibodies were investigated with standard laboratory techniques at VTE onset and were repeated during routine follow up visits [12, 14]. Especially, the analyses of protein C and protein S were performed at least three months after the index event and/or withdrawal of vitamin-K-antagonists and deficiency states of antithrombin, protein C or protein S were confirmed if values repeatedly persisted below the age-related reference ranges [14]. Criteria for the hereditary nature of a hemostatic defect were its presence in at least one further first or second-degree family member and/or the identification of a causative gene mutation.

Single nucleotide polymorphism [SNP] Genotyping for F2 A19911G (LRG_551t1:c.1726-59G>A, rs3136516) was performed by TaqMan PCR. The assay includes two allele specific TaqMan probes containing distinct fluorescent dyes and highly specific PCR primers to detect the target (Assay ID: C\_11661574\_10, ThermoFisher Scientific, RRID:SCR_018060). ABI 7900HT Fast Real-Time PCR System was used for analysis. Of note, the specific snip applied (rs3136516) does not show a significant deviation from Hardy Weinberg equilibrium in the healthy cohort of blood donors (p = 0.55).

Statistics

Statistical analyses were performed using the MedCalc® software bvba (version 16.4.3, Ostend, Belgium, RRID:SCR_015044) and StatView 5 software packages.
Continuous variables were expressed as mean (± standard deviation) or median [minimum–maximum] values and categorical data were expressed as counts and percentages. The Wilcoxon–Mann–Whitney-U-test investigated differences in continuous non-normal distributed variables between two independent groups. The Chi-square-test was used to analyze differences in binary and categorical data between for the primary study aim Odds ratios [OR] and their corresponding 95% confidence intervals [CI] were calculated using an univariable logistic regression model comparing patients with healthy controls (blood donors). The homozygous GG genotype and the heterozygous AG were compared with the AA wildtype (F2 at rs3136516). In order to evaluate an independent contribution to the risk of VTE and to adjust for further potential confounders (common IT, age at onset, blood group) [1–3, 13, 14] these variables were entered into a backward multivariable logistic regression model. In addition, to test for possible statistical interactions between F5 rs6025 and F2 rs313616 genotypes a multiplicative scale was incorporated in the model. Per “a priori” definition this backward model included variables with a p value of ≤0.2 and, vice versa, removed variables from the model if p was > 0.21. For the secondary study objective, i.e. the time to recurrence, we calculated the probability of VTE-free survival as a function of time utilizing the method of Kaplan and Meier (univariable analysis). The log rank test was used to test for differences in recurrence-free survival between groups. On the basis of previous reports (data presented in the Online Suppl. Tables 1 and 2) minimum sample size calculation for the comparison of two proportions was performed assuming a type I error of 0.05 and a type II error of 0.20 (sampling comparison of proportions) [18]. Patients were withdrawn from the survival analysis (censored cases) either at death unrelated to VTE recurrence or at loss to follow-up using data of the last clinical follow-up visit. In order to evaluate an independent contribution to the risk of recurrent VTE (dichotomous variables: recurrence “yes” versus “no recurrence”) and to adjust for further potential confounders (gender, common IT, age at first VTE onset, blood group) the hazard ratio (HR) together with 95% confidence intervals (CI) were estimated from Cox’s proportional hazards model. To further test the relationship between independent and dependent variables, the likelihood ratio test was performed. To test the proportional hazard assumption, one of the prerequisites for applying the Log-rank test or the Cox regression model fit, we used the cox.zph procedure in the package ‘survival’ (v3.1.8; Therneau TM, 2019) in R 3.4.3 [19]. A p value > 0.05 indicates no violation of the proportional hazard assumption. The recurrence rates were calculated as the number of recurrent events per 100 person-years.

**Ethics**

The underlying multicenter cohort study was approved by the medical ethics committee of the University of Münster & Kiel [B304/16], Germany and written informed consent was provided in all cases prior to study participation.

**Results**

Demographic data and thrombotic locations of patients (n = 1012) and healthy controls (n = 902) are depicted in Table 1. Frequency distribution of single & combined thrombophilic risk factors are given in Table 2 and in the online suppl.

**Primary study aim (univariable analysis: Table 3)**

Compared with the AA wildtype the GG genotype (rs3136516) increases the risk of VTE with an OR of 1.39 (CI 1.04–1.73) and 1.21 (CI 0.97–1.51) in carriers of the AG variant. In addition, in the cohort investigated the OR of F5 carriers compared to healthy blood donors was 6.35 (CI 4.59–8.77) and 2.44 (1.47–4.05) in patients with F2 (rs1799963). Combinations between the homozygous F2 GG genotype at rs3136516 and F5 at rs6025 did not significantly influence the thrombotic risk when comparing patient with controls (OR 0.56; CI 0.29–1.09) and combinations between the factor 2 rs1799963 GA/AA variants and the homozygous GG (rs3136516) genotype were neither detected in cases nor

| Table 1  | Patients with VTE n = 1012 | Healthy controls n = 902 |
|----------|---------------------------|--------------------------|
| Age      | 36.8 ± 10.9               | 37.8 ± 14                |
| Female   | 696 (68.8%)               | 443 (49.1%)              |
| VTE location at onset: n [%] |                     |                          |
| VTE leg  | 688 [68.0]                | –                        |
| VTE and PE | 192 [19.0]              | –                        |
| CSVT     | 61 [6.0]                  | –                        |
| Multiple | 32 [3.2]                  | –                        |
| VTE and ATE | 39 [3.9]              | –                        |
| Recurrent VTE location: n [%] |                     |                          |
| VTE leg  | 122 [68.5]                | –                        |
| VTE and PE | 1 [0.6]                  | –                        |
| CSVT     | 4 [2.2]                   | –                        |
| PE       | 47 [26.4]                 | –                        |
| VTE and ATE | 4 [2.2]              | –                        |

*ATE arterial embolism of venous origin, CSVT cerebral sinus vein thrombosis, NA does not apply, n number, PE pulmonary embolism, VTE venous thromboembolism*
in healthy controls, respectively. BG “non-O” was significantly more often found in patients with VTE compared to BG “O” (OR 3.77, CI 3.04–4.69). Furthermore, increasing age per year at first VTE onset enhances the VTE risk significantly by an OR of 1.01 (CI 1.02–1.04).

**Multivariable analysis (Table 3)**

Backward logistic regression showed that compared with the AA wildtype the GG genotype (rs3136516) was independently associated with a diagnosis of VTE with an OR of 1.48 (95% CI 1.06–2.06) and with the OR of 1.45 (95% CI 1.1–1.92) in carriers in which the AG variant was genotyped. In addition, the OR of F5 in patients compared to healthy blood donors was 5.68 (95% CI 3.94–8.20) and 2.38 (95% CI 1.35–4.20) in patients with F2 (rs1799963). BG “non-O” was significantly more often found in patients with VTE compared to BG “O” (OR 2.74; 95% CI 2.11–3.55). Again, as depicted in univariable analysis increasing age per year at first onset retained its significance also in multivariate analysis (OR 1.03; 95% CI 1.02–1.04). Due to the “a priori” defined statistical cut-off p-values combinations between F5 rs6025 and F2 rs3136516 (multiplicative scale) were removed from the multivariable model and were not included in the final analysis.

**Secondary study aim**

Within a mean time of 51.2 months (standard deviation: 43.5), recurrent VTE events (provoked 77%; locations depicted in Table 1) occurred in 178 out of 1012 patients (17.6%) following the first VTE onset (Fig. 1): 26.5% in men and 13.1% in women (p < 0.001). Gender associated incidence rates per 100 patient years (Table 4) were 4.3 (95% CI 3.4–5.3) in men and 1.9 (95% CI 1.6–2.4) in women (p < 0.0001). Further details of thrombotic locations and AC prior VTE recurrence are described in the online supplement material.

Whereas no significant associations were found between the risk of recurrent VTE and individuals classified as carriers of (i) the F2 mutation at rs3136516 “GG” subjects (OR 1.41; 95% CI 0.9–2.16) or in patients carrying (ii) the F2 rs179963 “GA” genotype (OR 1.81; 95% CI 0.87–3.76), results of the logistic regression model demonstrates that (iii) heterozygous F5 carriers had an increased OR of 1.86 (95% CI 1.22–2.83) to suffer from recurrent VTE with a further increase in patients additionally carrying the F2 GG/GA variant (rs3136516): OR 3.34 (95% CI 1.62–6.89). Patients with at least any IT compared to patients with no IT showed an increased odds ratio of 1.7 (95% CI 1.2–2.3) for a recurrence of VTE, while in patients with combined ITs the OR increased to 2.4 (95% CI 1.7–3.4). Of note, there was no significant association between the presence or absence of provoking risk factors and inherited thrombophilia (p = 0.93).
Fig. 1 Probability of recurrence-free survival (y-axis) following a first symptomatic VTE onset is depicted: 13.1% of women compared to 26.5% of men developed a second thrombotic event (log rank value: \( p < 0.0001 \)).

Fig. 2 Probability of recurrence-free survival (y-axis) following a first symptomatic VTE onset is depicted: 32.7% of patients carrying combined ITs compared to 15.6% without IT developed a second thrombotic event (log rank value: \( p < 0.0001 \)). In addition, recurrence-free survival in patients with any thrombophilia is depicted.

Table 4 Incidence rates of recurrent VTE per 100 patient years (gender and inherited thrombophilia) are depicted

| Type of inherited thrombophilia | Exposure time (years) | Event (n) | Incidence per 100 PY % (95% CI) | \( p \) value |
|--------------------------------|-----------------------|-----------|---------------------------------|-------------|
| Gender: male                   | 2014                  | 87        | 4.3 (3.4–5.3)                   | <0.0001     |
| Gender: female                 | 4690                  | 91        | 1.9 (1.6–2.4)                   |             |
| Any IT                         | 3578                  | 111       | 3.1 (2.6–3.7)                   | 0.089       |
| No IT                          | 2860                  | 67        | 2.4 (1.9–3.0)                   |             |
| Combined IT                    | 700                   | 34        | 4.8 (3.4–6.8)                   | 0.0006      |
| Total                          | 6704                  | 178       | 2.6 (2.3–3.1)                   |             |

\( CI \) confidence interval, \( PY \) patient years

Recurrence-free survival is depicted in Fig. 2: 32.7% of patients carrying combined ITs compared to 15.6% without IT developed a second thromboembolic event within 36 months (min–max: 1–120; log rank test: \( p < 0.0001 \)). Multivariable analysis including time to recurrence demonstrates that male gender [hazard ratio (HR) 2.3; 95% CI 1.7–3.0] and combined ITs (HR 2.11; 95% CI 1.5–3.0) showed a significant impact on the risk of VTE recurrence. Noteworthy, in this specific data set, gender, F5, F2 rs3136516, F2 rs179963 and blood group did not violate the proportional hazard assumption. Remarkably, age, both as continuous term or grouped into three equal sized groups did violate the proportional hazard assumption and was thus not included in the multivariable analysis. Due to the “a priori” defined statistical cut-off \( p \) values the comparison between BG O and non-O was removed from the multivariate model. Incidence rates of recurrence per 100 patient years are depicted in detail in Table 4.
Discussion

In the present longitudinal study in German patients with VTE we have shown that the presence of the F2 mutation at rs3136516 either in its GG or its GA genotype compared to the AA variant plays a moderate but independent role at first VTE onset with an adjusted odds ratio of 1.48 (GG genotype) and 1.45 (GA genotype), respectively. These findings were in agreement to study results described earlier in 2006 in an Italian cohort of patients (OR 1.5) and in line with data derived from the Netherlands with a 1.3-fold increased OR to suffer from VTE. As in our study, in the latter two cohorts the F2 rs3136516 GG genotypes were compared to AA carriers [8, 9]. The observation of a moderately enhanced association with VTE reported by us and by both cohorts published in 2006, however, is in contrast to findings reported by Perez-Ceballos et al. in 2002 and by Aradjanski et al. in 2014 [7, 10]. A summary of pooled data of previous reports [7–10] including our patients is depicted in the online supplement. Pooling results of over-
of new therapeutic approaches such as DOACs might have influenced referral and treatment patterns. (iv) Although we observed a large number of patients with common mild IT risk factors, this study might still be too small to show statistically significant differences. Although our findings in a clinical setting are in agreement with previously reported population-based studies [8, 9], higher patient numbers are needed to rule out statistical errors. (v) Finally, we may have missed recurrent thrombosis in the patients investigated: whereas we may have overlooked asymptomatic VTE recurrence, it is unlikely, however, that we would have missed symptomatic recurrences. This statement is underlined by the fact that the recurrence rates detected in this investigation are within the range reported by others [28, 29].

In conclusion, a Caucasian adolescent and adult patient with a first VTE onset, the F2 GG/GA genotypes (rs3136516) contribute to the first onset of the disease. Findings of this study gave evidence that patients with provoked VTEs (i) male gender and (ii) combined ITs, including the F2 mutation at rs3136516 may be regarded as important risk factors for VTE recurrence. These should be included in decision-making in regard to length of AC treatment. Whether (iii) blood group non-O should be included into a predictive scoring system, however, is part of an ongoing prospective study.

Acknowledgements Open Access funding provided by Projekt DEAL.

Author contributions U.N.G., B.K. and V.L. designed the study and analyzed the data. V.I., B.K., R.J., B. and U.N.G. wrote the paper. G.K., M.K., M.S., F.L., D.J., M.Sch., A.F., U.C.K., R.M., F.R., M.S., D.S., D.K., A.R., P.K., T.B., A.T. and B.N. had full access to the data and took part in the design, execution and data analysis, discussion, and in writing the report. The manuscript has been read and approved for submission to the Journal of Thrombosis and Haemostasis by all authors.

Funding The study was supported by grants from the Förderein “Schlaganfall und Thrombosen im Kindesalter e.V.”, Interdisziplinäres Zentrum für Klinische Forschung (IZKF: CRA01-09: University of Münster) and the “Gesellschaft für Thrombose und Hämostaseforschung/ Society of Thrombosis and Hemostasis Research” [GTH (Grant 2016)]. None of the aforementioned funding agencies had a role in study design, conduct, interpretation, or reporting.

Compliance with ethical standards

Conflict of interest Verena Limperger: personal fees from Bristol-Myers Squibb, Amedes holding GmbH, CSL Behring, NovoNordisk, non-financial support from Octapharma, NovoNordisk, outside the submitted work. Gili Kenet: personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from Daiichi Sankyo, other from Pfizer, outside the submitted work. Bettina Kiesau: personal fees and other from SoBi, outside the submitted work. Max Köther, Malin Schmeiser, David Juhl, Andre Franke, Ulrich K. Klostermeier, Rolf Mesters, Frank Rühle, Monika Stoll, Dagmar Steppat, Antje Torge, Bruno Neuner, and Ralf Junker declared that they have no conflict of interest. Florian Langer: personal fees from Bayer, personal fees from Bristol-Myers Squibb, personal fees from Daiichi Sankyo, personal fees from LEO Pharma, grants and personal fees from Pfizer, personal fees from Chugai, personal fees from Roche, personal fees from SoBi, personal fees from Takeda, personal fees from CSL, Behring, personal fees from SoBi, personal fees from Werfen, personal fees from Siemens, personal fees from Grifols, personal fees from Novo Nordisk, personal fees from Octapharma, personal fees from Ablynx, outside the submitted work. Maria Shneyder: personal fees from Novo Nordisk, Octapharma and Takeda, outside the submitted work. Dorothée Kowalski: non-financial support from Octapharma, Novo Nordisk and LFB GmbH outside the submitted work. Angela Rocke: personal fees from Octapharma, CSL Behring outside the submitted work. Piotr Kuta: personal fees from CSL Behring, Novo Nordisk, Octapharma, Stago, Aspen outside the submitted work. Tido Bajorat: personal fees from BFSH e.V. (Bündnis zur Förderung der Sicherheit von Hämostafen), personal fees from Octapharma, outside the submitted work. Ulrike Nowak-Göttl: grants from Octapharma, grants from LFB, other from Bayer Vital, other from Boehringer-Ingelheim, outside the submitted work.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Rosendaal FR (1999) Venous thrombosis: a multicausal disease. Lancet 353:1167–1173. https://doi.org/10.1016/S0140-6736(98)10266-0
2. Dahlbäck B (2000) Blood coagulation. Lancet 355:1627–1632. https://doi.org/10.1016/S0140-6736(00)02225-X
3. Martinelli I (2001) Risk factors in venous thromboembolism. Thromb Haemost 86:395–403
4. Bertina RM, Koelman BP, Koster T et al (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67. https://doi.org/10.1038/369064a0
5. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703
6. Cleeie H, Bertina RM, van Hylckama VA et al (2001) Polymorphisms in the prothrombin gene and their association with plasma prothrombin levels. Thromb Haemost 85:1066–1070
7. Pérez-Ceballos E, Corral J, Alberca I et al (2002) Prothrombin A19911G and G20210A polymorphisms’ role in thrombosis. Br J Haematol 118:610–614. https://doi.org/10.1046/j.1365-2451.2002.02394.x
8. Martinelli I, Battaglioti T, Tosetto A et al (2006) Prothrombin A19911G polymorphism and the risk of venous thromboembolism. J Thromb Haemost 4:2582–2586. https://doi.org/10.1111/j.1538-7836.2006.02216.x
9. Chinthammitr Y, Vos HL, Rosendaal FR, Doggen CJM (2006) The association of prothrombin A19911G polymorphism with plasma prothrombin activity and venous thrombosis: results
of the MEGA study, a large population-based case-control study. J Thromb Haemost 4:2587–2592. https://doi.org/10.1111/j.1538-7836.2006.02257.x

10. Aradjanski M, Djordjevic V, Pruner I et al (2014) The 3′ end prothrombin gene variants in Serbian patients with idiopathic thrombophilia. Balk J Med Genet 17:43–48. https://doi.org/10.2478/bjmg-2014-0073

11. Soria JM, Almasy L, Souto JC et al (2000) Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood 95(9):2780–2785

12. Holzhauer S, Goldenberg NA, Junker R et al (2012) Inherited thrombophilia in children with venous thromboembolism and the familial risk of thromboembolism: an observational study. Blood 120:1510–1515. https://doi.org/10.1182/blood-2012-01-405514

13. Anderson FA, Wheeler HB, Goldberg RJ et al (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med 151:933–938. https://doi.org/10.1001/archinte.1991.00400050081016

14. Nowak-Göttl U, Limperger V, Kenet G et al (2017) Developmental hemostasis: a lifespan from neonates and pregnancy to the young and elderly adult in a European white population. Blood Cells Mol Dis. https://doi.org/10.1016/j.bcmd.2016.11.012

15. Kearon C, Akk EA, Ornelas J et al (2016) Antithrombotic Therapy for VTE Disease. Chest 149:315–352. https://doi.org/10.1016/j.chest.2015.11.026

16. Monagle P, Chan AKC, Goldenberg NA et al (2012) Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e737S–801S. https://doi.org/10.1378/chest.11-2308

17. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2015) S3 Leitlinie Prophylaxe der venösen Thrombembolie (VTE). 1–238

18. Machin D, Campbell MJ, Tan SB, Tan SH (2008) Sample size tables for clinical studies. Wiley-Blackwell, Oxford

19. Therneau TM, Grambsch PM (2000) Modeling survival data: extending the Cox model. Springer, New York

20. Lindström S, Wang L, Smith EN et al (2019) Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. Blood 134:1645–1657. https://doi.org/10.1182/blood.2019000435

21. Franchini M, Mannucci PM (2014) ABO blood group and thrombotic vascular disease. Thromb Haemost 112:1103–1109. https://doi.org/10.1111/thh.12473

22. Douketis J, Tosetto A, Marcucci M et al (2011) Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 342:d813. https://doi.org/10.1136/bmj.d813

23. McRae S, Tran H, Schulman S et al (2006) Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 368:371–378. https://doi.org/10.1016/S0140-6736(06)69110-1

24. Kearon C, Parpia S, Spencer FA et al (2019) Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results: A cohort study. J Thromb Haemost 17:1144–1152. https://doi.org/10.1111/jth.14458

25. Normann S, de Veber G, Fokker M et al (2009) Role of endogenous testosterone concentration in pediatric stroke. Ann Neurol 66:754–758. https://doi.org/10.1002/ana.21840

26. Freedman J, Glueck CJ, Prince M et al (2015) Testosterone, thrombophilia, thrombosis. Transl Res 165:537–548. https://doi.org/10.1016/j.trsl.2014.12.003

27. DeVeber G, Kirkham F, Shannon KK et al (2019) Recurrent stroke: the role of thrombophilia in a large international pediatric stroke population. Haematologica. https://doi.org/10.3324/haematol.2018.211433

28. Vossen CY, Walker ID, Svensson P et al (2005) Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 25:1992–1997. https://doi.org/10.1161/01.ATV.0000174806.76629.7b

29. Heit JA (2012) Predicting the risk of venous thromboembolism recurrence. Am J Hematol 87:S63. https://doi.org/10.1002/ajh.23128

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

Verena Limperger1 ⋆, Gili Kenet2,3, Bettina Kiesau4, Max Köther1, Malin Schmeiser1, Florian Langer4, David Juhl5, Maria Shnedyer2, Andre Franke6, Ulrich K. Klostermeier1, Rolf Mesters7, Frank Rühle8, Monika Stoll8,9, Dagmar Steppat5, Dorothee Kowalski1, Angela Rocke1, Piotr Kuta1, Tido Bajorat1, Antje Torge1, Bruno Neuner10, Ralf Junker1, Ulrike Nowak-Göttl1

1 UKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel 24105, Germany
2 National Hemophilia Center, Institute of Thrombosis and Hemostasis, Sheba Medical Centre, Tel-Hashomer, Israel
3 The Amalia Biron Research Institute of Thrombosis and Hemostasis, Tel Aviv University, Tel Aviv, Israel
4 Department of Hematology & Oncology, Univ. Hospital Hamburg, Hamburg, Germany
5 Institute of Transfusion Medicine, Univ. Hospital Kiel & Lübeck, Lübeck, Germany
6 Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany
7 Department of Medicine/ Hematology & Oncology, Univ. Hospital Münster, Münster, Germany
8 Institute of Human Genetics, Westfälische-Wilhelms-University, Münster, Germany
9 Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
10 Department of Anesthesiology and Intensive Care Medicine, Charité – Universitätsmedizin Berlin, Campus Charité Mitte and Campus Virchow-Klinikum, Berlin, Germany